Company intelligence / Profile preview

EpiPharm AG

Binningen, Basel-Landschaft, Switzerlandepipharm.ch ↗

Ownership: Private
Employees: ~15
Development stage: Clinical

Overview

EpiPharm AG is a clinical-stage biopharmaceutical company developing innovative, non-invasive, take-home topical products for the treatment of benign skin tumors and hyperpigmentation disorders. Its lead product, EPI-SK17, targets the underlying causes of seborrheic keratosis. The company focuses on solutions that can be used at home and are non-invasive alternatives to current treatments.[1][2] No detailed clinical results are publicly available.

Therapeutic areas: Dermatology
Modalities: Topical therapiesNon-invasive products
Industry: Biotech

Drug pipeline

5 assets

Epi SP

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

Not explicitly listed; open to collaborations per website contact section.[4]

Beyond the preview

Go deeper on EpiPharm AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiPharm AG.

Explore the full profile